Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q4 FY25 results · Jan–Mar 2025
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,055.55 crore and net profit of ₹149.61 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,055.55 | — | — | 1,010.41 | +4.5% |
| Other income | 17.55 | — | — | 14.56 | +20.5% |
| Total income | 1,073.09 | — | — | 1,024.97 | +4.7% |
| Profit before tax | 75.14 | — | — | 91.05 | −17.5% |
| Net profit for the period | 149.61 | — | — | 66.31 | +125.6% |
| Attributable to shareholders of the company | 147.62 | — | — | 65.18 | +126.5% |
| EPS, basic (₹) | 9.64 | — | — | 4.26 | not comparable |
| Net margin (%) | 14.2 | — | 6.6 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.75 | — | — | 337.41 | −2.6% |
| Other income | 32.05 | — | — | 33.84 | −5.3% |
| Total income | 360.80 | — | — | 371.25 | −2.8% |
| Profit before tax | 37.05 | — | — | 54.89 | −32.5% |
| Net profit for the period | 27.59 | — | — | 41.17 | −33.0% |
| EPS, basic (₹) | 1.80 | — | — | 2.69 | −33.1% |
| Net margin (%) | 8.4 | — | 12.2 |
Consolidated
- Filed with BSE
- 26 May 2025, 19:08 IST
- Board meeting
- 26 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2025, 19:08 IST
- Board meeting
- 26 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE